Market closed

Moderna/$MRNA

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Moderna

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Ticker

$MRNA

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Cambridge, United States

Employees

5,600

Website

www.modernatx.com

Moderna Metrics

BasicAdvanced

$14B

-

-$5.82

1.69 -

Price and volume

Market cap

$14B

Beta

1.69

52-week high

$170.47

52-week low

$31.94

Average daily volume

8.9M

Financial strength

Current ratio

4.392

Quick ratio

3.831

Long term debt to equity

10.933

Total debt to equity

11.361

Interest coverage (TTM)

-48.09%

Management effectiveness

Return on assets (TTM)

-9.55%

Return on equity (TTM)

-17.52%

Valuation

Price to revenue (TTM)

2.648

Price to book

1.13

Price to tangible book (TTM)

1.14

Price to free cash flow (TTM)

-3.401

Growth

Revenue change (TTM)

-44.29%

Earnings per share change (TTM)

-35.66%

3-year revenue growth (CAGR)

-24.55%

3-year earnings per share growth (CAGR)

-29.65%

What the Analysts think about Moderna

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Moderna stock.

Moderna Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

Moderna Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Moderna News

AllArticlesVideos

ME Therapeutics Announces That Its First Therapeutic mRNA Candidate Shows Encouraging Anti-Cancer Efficacy in Vivo

Newsfile Corp·14 hours ago

Watch These Moderna Price Levels as Stock Plummets After Slashing 2025 Revenue Outlook

Investopedia·1 day ago

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

Seeking Alpha·1 day ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MRNA

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Moderna stock?

Moderna (MRNA) has a market cap of $14B as of January 15, 2025.

What is the P/E ratio for Moderna stock?

The price to earnings (P/E) ratio for Moderna (MRNA) stock is 0 as of January 15, 2025.

Does Moderna stock pay dividends?

No, Moderna (MRNA) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Moderna dividend payment date?

Moderna (MRNA) stock does not pay dividends to its shareholders.

What is the beta indicator for Moderna?

Moderna (MRNA) has a beta rating of 1.69. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.